BiosimilarBiological
PF-05280586 clinical trials
Also written PF-05280586.
A product of Rituximab; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 1
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 1
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses PF-05280586 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)CompletedPhase 2PfizerNCT01526057Written as PF-05280586
- A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)CompletedPhase 3PfizerNCT02213263Written as PF-05280586
- Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)CompletedNot applicablePfizerNCT01643928Written as Rituximab-Pfizer (PF-05280586) x 3 courses